Eli Lilly and Nvidia announced a major collaboration to launch an artificial intelligence co-innovation lab. Unveiled at the J.P. Morgan Healthcare Conference, the partnership commits a joint investment of up to $1 billion over five years. The primary goal is leveraging AI to accelerate the discovery of new medicines.
The new lab will be based in the San Francisco Bay Area, bringing together Lilly’s scientists and Nvidia’s AI engineers. The initiative utilizes Nvidia’s BioNeMo platform. This technology will generate large-scale data and develop powerful AI models.
The collaboration aims to create a continuous learning system connecting lab experiments with computational models. This system seeks to shorten the timeline between hypothesis and the discovery of new treatments. The partnership deepens the existing relationship between the two firms, following Lilly’s 2025 announcement to build an AI supercomputer with Nvidia.